PathAI has launched the PathAssist Derm AI tool, which is designed for orienting, detecting, and measuring skin lesions.

This new offering, now available on the AISight image management system (IMS), aims to improve dermatopathology research workflows.

PathAssist Derm eliminates the necessity for manual orientation of glass slides by automating the process of specimen orientation.

It also aids in the evaluation of skin specimens and is claimed to predict the presence of 17 different skin lesion entities.

These include both common and rare entities, ranging from actinic keratoses and basal cell carcinomas to lichenoid keratoses and melanomas.

By collaborating with various laboratories, the company is planning to explore the potential efficiency gains that the tool could offer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As part of the AISight IMS, the tool joins the suite of AI-driven solutions that help pathologists deliver ‘precise’ and ‘actionable’ insights required for diagnostic research.

The cloud-native AISight platform is a central hub for case and image management, integrating with major laboratory information systems and supporting a range of scanners.

PathAssist Derm is said to be the first dermatopathology AI offering on this platform.

It is important to note that the tool is intended for research use only and is not approved for use in diagnostic procedures.

PathAI CEO and co-founder Andrew Beck said: “Skin cancer remains the most prevalent cancer worldwide, with over 1.5 million new cases diagnosed annually, which are associated with 60,000 deaths from melanoma alone.

“These statistics present a critical opportunity for innovation in skin cancer research, both in the diagnostic and therapeutic realms. Our goal with PathAssist Derm is to provide researchers with a scalable tool that enhances dermatopathology research through AI-enabled lesion characterisation and workflow efficiency, as part of our overall vision to improve patient outcomes with AI-powered pathology.”